Multiple myeloma patients get continued access to promising drug in extension trial

NCT ID NCT05669989

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated May 14, 2026

Summary

This study offers continued access to the drug isatuximab for adults with multiple myeloma who are still benefiting from it after finishing an earlier clinical trial. The main goal is to monitor long-term safety. About 70 participants will receive the treatment and be watched for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Hospital Mae de Deus- Site Number : 0760003

Porto Alegre, Rio Grande do Sul, 90880-480, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP- Site Number : 0760002

São Paulo, São Paulo, 05403-010, Brazil
Instituto Americas - Ensino, Pesquisa e Inovação - Rio de Janeiro - Avenida Jorge Curi- Site Number : 0760001

Rio de Janeiro, 22775-001, Brazil
Investigational Site Number : 0360001

Saint Leonards, New South Wales, 2065, Australia
Investigational Site Number : 0360002

Richmond, Victoria, 3121, Australia
Investigational Site Number : 0360003

Wollongong, New South Wales, 2500, Australia
Investigational Site Number : 0360004

Melbourne, Victoria, 3065, Australia
Investigational Site Number : 0360005

Melbourne, Victoria, 3084, Australia
Investigational Site Number : 0360006

Blacktown, New South Wales, 2148, Australia
Investigational Site Number : 1520001

Temuco, 4780000, Chile
Investigational Site Number : 1560001

Tianjin, 300020, China
Investigational Site Number : 1580001

Taichung, 404, Taiwan
Investigational Site Number : 2030001

Prague, 128 08, Czechia
Investigational Site Number : 2030002

Brno, 625 00, Czechia
Investigational Site Number : 2030003

Ostrava, 708 52, Czechia
Investigational Site Number : 2460001

Helsinki, 00029, Finland
Investigational Site Number : 2500002

Nantes, 44093, France
Investigational Site Number : 3000001

Pátrai, 265 04, Greece
Investigational Site Number : 3000003

Athens, 115 28, Greece
Investigational Site Number : 3000004

Athens, 106 76, Greece
Investigational Site Number : 3800002

Torino, 10126, Italy
Investigational Site Number : 3920001

Okayama, 701-1192, Japan
Investigational Site Number : 4100001

Seoul, Seoul-teukbyeolsi, 03080, South Korea
Investigational Site Number : 4100002

Seoul, Seoul-teukbyeolsi, 06591, South Korea
Investigational Site Number : 5540001

Wellington, 6021, New Zealand
Investigational Site Number : 5540002

Auckland, 2025, New Zealand
Investigational Site Number : 6430001

Moscow, 125284, Russia
Investigational Site Number : 6430002

Kirov, 610027, Russia
Investigational Site Number : 7240001

Pamplona, Navarre, 31008, Spain
Investigational Site Number : 7240002

Salamanca, 37007, Spain
Investigational Site Number : 7240003

Madrid, 28041, Spain
Investigational Site Number : 7240004

Santander, Cantabria, 39008, Spain
Investigational Site Number : 7240005

Badalona, Catalunya [Cataluña], 08916, Spain
Investigational Site Number : 7240006

Seville, Andalusia, 41013, Spain
Investigational Site Number : 7241001

Madrid, Madrid, Comunidad de, 28027, Spain
Investigational Site Number : 7520004

Luleå, 971 80, Sweden
Washington University- Site Number : 8400001

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

PLASMA CELL MYELOMA